Back to Single Peptide Protocols
Single PeptideHormonal & Sexual Health10 mg vialAs neededSubcutaneousMelanocortin
PT-141 / Bremelanotide (10 mg Vial) Dosage Protocol
PT-141 (Bremelanotide) dosage protocol for the 10 mg vial. FDA-approved melanocortin receptor agonist for HSDD.
Vial Size
10 mg
Route
Subcutaneous
Frequency
As needed (45 min before activity)
Dose Range
1.75 mg per dose
Dosage Schedule
| Period | Dose |
|---|---|
| Starting dose | 1.75 mg |
| Maximum dose | 1.75 mg (max 1× per 24h) |
Route: Subcutaneous · Frequency: As needed (45 min before activity) · Cycle: As needed
How It Works
PT-141 (Bremelanotide) is a melanocortin receptor agonist (MC3R/MC4R) that acts centrally on the hypothalamus to increase sexual desire. It is the active ingredient in Vyleesi, FDA-approved for HSDD in premenopausal women.
Potential Benefits
- •FDA-approved (Vyleesi) for hypoactive sexual desire disorder (HSDD).
- •Central mechanism of action — works on brain, not vasculature.
- •Effective in both men and women in research settings.
Side Effects & Risks
- •Nausea (most common — up to 40% in trials).
- •Transient blood pressure increase.
- •Flushing, headache.
- •Hyperpigmentation with chronic use.
Important Notes
- Administer 45 minutes before anticipated sexual activity.
- Do not use more than once per 24 hours.
- FDA-approved as Vyleesi for HSDD in premenopausal women.
Storage Instructions
- Lyophilized: −20 °C (−4 °F).
- Once mixed: 2–8 °C; use within 30 days.
References
- [1]Vyleesi (bremelanotide) Prescribing Information. AMAG Pharmaceuticals 2019.View Source
Research & Educational Use Only: This protocol is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any decisions related to peptides or any other compounds.